AstraZeneca acquires Amolyt in $1B deal

137
SHARE

In conclusion, AstraZeneca’s acquisition of Amolyt Pharma represents a pivotal step towards expanding its rare disease pipeline and delivering innovative treatment solutions to patients worldwide.